Abstract
BackgroundUpadacitinib (UPA), a Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in patients (pts) with ankylosing spondylitis (AS) in the phase 3 SELECT-AXIS 1 and 2 program,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
